Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
You are hereHome › For Physicians
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
We focus on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
Combination with 1st Line Chemo (SYNERGY)
Combination with 2nd Line Chemo (AFFINITY)
Non-Small Cell Lung Cancer
Combination with Chemotherapy (ENSPIRIT)
Combination with prednisone (pre-chemo)
Combination with Zytiga pre or post-chemo (Pacific)
Combination with 1st Line Chemo (metastatic)(Borealis-1)
Combination with 2nd Line Chemo (metastatic)(Borealis-2)
Combination with 1st Line Chemo (Spruce)
Combination with 1st line Chemo (metastatic) (Rainier)